A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Stopped The study was discontinued due to slow recruitment and subjects not completing follow up period.

Conditions

• Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
• LA SCCHN

Interventions

• DRUG: Cetuximab + RT

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

• [object Object]